He pointed out that frequent anti-VEGF injections into the eye can be a significant burden, and many patients with DME are of ...

In this Healio Video Perspective from the Congress on Controversies in Ophthalmology, Patricia Udaondo, MD, PhD, highlights ...

Retinal pigment epithelial detachment is associated with neovascular age-related macular degeneration in 30% to 80% of cases, according to the literature.It is often difficult to treat, requires a ...

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope ...

Medically reviewed by Andrew Greenberg, MD Optometrists (healthcare providers who offer standard eye care) can diagnose wet age-related macular degeneration (AMD) but can't treat it. Therapies for wet ...

Anti-VEGF injections are commonly used to treat macular edema due to RVO. There are two main types of RVO: central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).

The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application ...

The study included patients who had been on long-term ranibizumab for the treatment of wet AMD and had switched to intravitreal aflibercept injection. Inclusion criteria were as follows ...

reducing the number of injections by half compared to all other anti-VEGF therapies. The application is backed by data from across the EYLEA HD clinical program, including the Phase 3 QUASAR trial ...